Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance

A History of Cancer Chemotherapy

Vincent T. DeVita, Edward Chu · Cancer Research · 2008 · 1.9K citations · Full text

Medicine, Oncology, Pharmacology +12

Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects

Ana-Maria Florea, Dietrich Büsselberg · Cancers · 2011 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 818 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance

Yogesh Patil, Tanmoy Sadhukha, Linan Ma et al. · Journal of Controlled Release · 2009 · 313 citations

Pharmacy, Pharmaceutics, Pharmacology +16